FX.co ★ Teva Pharma To Divest Teva-Takeda Business Venture In Japan To JKI

Teva Pharmaceutical Industries Ltd. has declared its intention to sell its Japanese arm, Teva-Takeda, to JKI Co., Ltd. This transaction covers its portfolio of generic and legacy products, enabling Teva to concentrate on delivering its innovative medications to the Japanese market. Under the agreement, all shares of Teva Takeda Pharma Limited and its wholly-owned subsidiary, Teva Takeda Yakuhin Ltd., will be transferred to JKI. Teva anticipates finalizing the sale by April 1, 2025, pending customary closing conditions, including necessary regulatory approvals. The agreement ensures the continued employment of all current staff in Japan.